Octubre-Diciembre 2017 72
ISSN 1317-987X


Mecanismo de acción de la insulina. (Revisión)


1. White MF. Longevity. Mapping the path to a longer life. Nature 524:170-171, 2015.

2. Levine R, Goldstein M, Klein S and Huddelston B. 1949. The action of insulin on the distribution of galactose in eviscerated and nephrectomized dogs. J Biol Chem 179:985-986.

3. De Meyts P. 2004. Insulin and its receptor: structure, function and evolution. BioEssays 26:1351-1362.

4. Petruzzelli LM, Ganguly S, Smith CJ, Cobb MH, Rubin CS and Rosen OM. 1982. Insulin activates a tyrosine-specific protein kinase in extracts of 3T3-L1 adipocytes and human placenta. Proc Natl Acad Sci USA 79:6792-6796.

5. Ebina Y, Ellis L, Jamagin K, Edery M, Graf L, Clauser E, Ou J-H, Masiarz F, Kan YW, Goldfine ID, Roth RA and Rutter WJ. 1985. The human insulin receptor cDNA: the structural basis for hormone-activated transmembrane signalling. Cell 40:747-758.

6. Ullrich A, Bell JR, Chen EY, Herrera R, Petruzelli LM, Dull TJ, Gray A, Coussens L, Liao YC, Tsubokawa M, Mason A, Seeburg PH, Grunfeld C, Rosen M and Ramachandran J. 1985.Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes. Nature 313:765-761.

7. De Meyts P. 2016. The Insulin Receptor and Its Signal Transduction Network. De Groot LJ, Chrousos G, Dungan K, et al., editors. South Dartmouth (MA): MDText.com, Inc.; 2000-.

8. De Meyts P and Whittaker J. 2002 Structural biology of insulin and IGF1 receptors: implications for drug design. Nat Rev Drug Disc 1: 769-783.

9. Sparrow LG, McKern NM, Gorman JJ, Strike PM, Robinson CP, Bentley JD, Ward CW. 1997. The disulfide bonds in the C-terminal domains of the human insulin receptor ectodomain. J Biol Chem 272: 29460–29467.

10. Hubbard SR. 2013. The insulin receptor: both a prototypical and atypical receptor tyrosine kinase. Cold Spring Harb Perspect Biol. 1; 5 (3) 2013.

11. Smith BJ, Huang K, Kong G, Chan SJ, Nakagawa S, Menting JG, Hu SQ, Whittaker J, Steiner DF, Katsoyannis PG, Warda CW, Weissb MA, and Lawrenceal MC. 2010. Structural resolution of a tandem hormone-binding element in the insulin receptor and its implications for design of peptide agonists. Proc Natl Acad Sci 107: 6771–6776.

12. Whittaker L, Hao C, Fu W, Whittaker J. 2008. High-affinity insulin binding: Insulin interacts with two receptor ligand binding sites. Biochemistry 47: 12900–12909.

13. Hubbard SR. 1997. Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog. EMBO J 16: 5572–5581.

14. De Meyts P. 2008. The insulin receptor: A prototype for dimeric, allosteric membrane receptors? Trends Biochem Sci 33: 376–384.

15. Ward CW and Lawrence MC. 2012. Similar but different: Ligand-induced activation of the insulin and epidermal growth factor receptor families. Curr Opin Struct Biol 22: 360–366.

16. Li S, Covino ND, Stein EG, Till JH, Hubbard SR. 2003. Structural and biochemical evidence for an autoinhibitory role for tyrosine 984 in the juxtamembrane region of the insulin receptor. J Biol Chem 278: 26007–26014.

17. Hubbard SR, Wei L, Ellis L, Hendrickson WA. 1994. Crystal structure of the tyrosine kinase domain of the human insulin receptor. Nature 372: 746–754.

18. Wei L, Hubbard SR, Hendrickson WA, Ellis L. 1995. Expression, characterization, and crystallization of the catalytic core of the human insulin receptor protein-tyrosine kinase domain. J Biol Chem 270: 8122–8130.

19. Wu J, Li W, Craddock BP, Foreman KW, Mulvihill MJ, Ji QS, Miller WT, Hubbard SR. 2008. Small-molecule inhibition and activation-loop trans-phosphorylation of the IGF1 receptor. EMBO J 27: 1985–1994.

20. Taniguchi CM, Emanuelli B and Kahn CR. 2006. Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol 7: 85-96.

21. Versteyhe S, Blanquart C, Hampe C, Mahmood S, Christoff N, De Meyts P, Gray SG and Issad T. 2010. IRS-5 and -6 are poor substrates for the insulin receptor. Mol Med Rep 3:189-193.

22. Cantley LC. 2002. The phosphoinositide 3-kinase pathway. Science 296:1655-1657.

23. Avruch J. 2007. MAP kinase pathways: the first twenty years. Biochim Biophys Acta 1773:1150-1160.

24. Harris TE and Lawrence JC Jr. 2003. TOR signaling. Sci. STKE 2003, RE 15.

25. Cohen P. 2001. The renaissance of GSK3. Nat Rev Mol Cell Biol 2:767-776.

26. Accili D and Arden KC. 2004. FoxOs at the crossroads of cellular metabolism, differentiation and transformation. Cell117:421-426.

27. Svendsen AM, Winge SB, Zimmermann M, Lindvig AB, Warzecha CB, Sajid W, Horne MC and De Meyts P, 2014. Downregulation of cyclin G2 by insulin, IGF-I (insulin-like growth factor 1) and X10 (Asp B10 insulin):role in mitogenesis. Biochem J 457:69-77.

28. Sano H, Kane S, Sano E, Miiner CP, Asara JM, Lane WS, Garner CW and Lienhard GE. 2003. Insulin-stimulated phosphorylation of Rab GTPase-activating protein regulates GLUT4 translocation. J Biol Chem 278:14599-14602.

29. Yu Q, Gao F and Ma XL 2011. Insulin says NO to cardiovascular disease. Cardiovasc Res 89: 516–524

30. Thong FSL, Dugani CB and Klip A. 2005. Turning Signals On and Off: GLUT4 Traffic in the Insulin-Signaling Highway. Physiology 20: 271-284.

31. Huang S and Czech MP. . 2007. The GLUT4 glucose transporter. Cell Metab 5:237-252

32. Satoh S, Nishimura H, Clark AE, Kozka IJ, Vannucci SJ, Simpson IA, Quon MJ, Cushman SW, and Holman GD. 1993. Use of bismannose photolabel to elucidate insulin-regulated GLUT4 subcellular trafficking kinetics in rat adipose cells. Evidence that exocytosis is a critical site of hormone action. J Biol Chem 268: 17820–17829.

33. Eguez L, Lee A, Chavez JA, Miinea CP, Kane S, Lienhard GE, and McGraw, TE. 2005. Full intracellular retention of GLUT4 requires AS160 Rab GTPase activating protein. Cell Metab; 2: 263–272

34. Farese R. V. 2002. Function and dysfunction of aPKC isoforms for glucose transport in insulin-sensitive and insulin resistant states. Am. J. Physiol. Endocrinol. Metab. 283, E1–E11.

35. Farese R V. Sajan MP. and Standaert ML. 2005. Atypical protein kinase C in insulin action and insulin resistance. Biochem. Soc. Trans. 33, 350–353.

36. Chiang SH, Baumann CA, Kanzaki M, Thurmond DC, Watson RT, Neudauer CL, Macara IG, Pessin JE, and Saltiel AR. 2001. Insulin-stimulated GLUT4 translocation requires the CAP-dependent activation of TC10. Nature 410: 944–948.

37. Tong P, Khayat ZA, Huang C, Patel N, Ueyama A, and Klip A. 2001. Insulin-induced cortical actin remodeling promotes GLUT4 insertion at muscle cell membrane ruffles. J Clin Invest 108: 371–381.

38. Wang Q, Somwar R, Bilan PJ, Liu Z, Jin J, Woodgett JR, and Klip A. 1999. Protein kinase B/Akt participates in GLUT4 translocation by insulin in L6 myotubes. Mol Cell Biol 19: 4008–4018.

39. Kanzaki M and Pessin JE. 2001. Insulin-stimulated GLUT4 translocation in adipocytes is dependent upon cortical actin remodeling. J Biol Chem 276: 42436–42444.

40. González-Mujica F. 2016. Drogas antidiabéticas diferentes de la insulina. Mecanismos de acción. Vitae. Abril-Junio Nº 66. Disponible en: http://vitae.ucv.ve/?module=articulo&rv=124&n=5316.

41. Gual P, Marchand-Brustel Y, and Tanti JF. 2005.Positive and negative regulation of insulin signaling through IRS-1 phosphorylation. Biochimie 87: 99–109.

42. Galic S, Hauser C, Kahn BB, Haj FG, Neel BG, Tonks NK, and Tiganis T. 2005. Coordinated regulation of insulin signaling by the protein tyrosine phosphatases PTP1B and TCPTP. Mol Cell Biol 25: 819–829.

43. Ugi S, Imamura T, Maegawa H, Egawa K, Yoshizaki T, Shi K, Obata T, Ebina Y, Kashiwagi A, and Olefsky JM. 2004. Protein phosphatase 2A negatively regulates insulin’s metabolic signaling pathway by inhibiting Akt (protein kinase B) activity in 3T3-L1 adipocytes. Mol Cell Biol 24: 8778–8789.

44. Ono H, Katagiri H, Funaki M, Anai M, Inukai K, Fukushima Y, Sakoda H, Ogihara T, Onishi Y, Fujishiro M, Kikuchi M, Oka Y, and Asano T. 2001. Regulation of phosphoinositide metabolism, Akt phosphorylation, and glucose transport by PTEN (phosphatase and tensin homolog deleted on chromosome 10) in 3T3-L1 adipocytes. Mol Endocrinol 15: 1411–1422.

45. Carpentier JL. 1994. Insulin receptor internalization: molecular mechanisms and pathophysiological implications. Diabetologia 37 Suppl 2: S117-S124

46. Duckworth WC, Bennett RG and Hamel FG. 1998. Insulin degradation: progress and potential. Endocr Rev. 19: 608-624.

Mecanismo de acción de la insulina. (Revisión)
Receptor de Insulina
Transducción intracelular de la señalización de la insulina
Finalización de la señal y mecanismos de retroalimentación negativos

NOTA: Toda la información que se brinda en este artículo es de carácter investigativo y con fines académicos y de actualización para estudiantes y profesionales de la salud. En ningún caso es de carácter general ni sustituye el asesoramiento de un médico. Ante cualquier duda que pueda tener sobre su estado de salud, consulte con su médico o especialista.

Instituto de Medicina Tropical - Facultad de Medicina - Universidad Central de Venezuela.
Elaborado por el Centro de Análisis de Imágenes Biomédicas Computarizadas CAIBCO,
Este portal ha sido desarrollado gracias al apoyo del Fonacit